DBV Technologies

174 articles with DBV Technologies

• Company Profile for DBV Technologies

  9/27/2013

• DBV Technologies Initiates a Long-Term Follow-Up Study of Viaskin Peanut

  9/4/2013

• DBV Technologies Reports Financial Results for the First Six Months of 2013

  7/26/2013

• DBV Technologies Completes Enrollment of Phase IIb VIPES Study, the First-Ever Global Trial in Desensitization to Peanut Allergy

  7/8/2013

• DBV Technologies: Viaskin Peanut Demonstrates Strong Efficacy Trend in Severely Peanut-Allergic Children in 18-Month Results of ARACHILD Pilot Study

  6/21/2013

• DBV Technologies Proudly Welcomes Mrs. Veronique Foutel as Chief Strategic Marketing Officer

  6/6/2013

• DBV Technologies and Stallergenes, S.A. Enter Into Partnership for the Development of Innovative Treatment of Respiratory Allergies

  5/17/2013

• DBV Technologies and Mount Sinai Hospital Enter Into a Research Collaboration Agreement

  5/7/2013

• DBV Technologies Publishes Its 2012 Registration Document and Its 2012 Annual Financial Report

  4/25/2013

• DBV Technologies, Sanofi (France) Sign Manufacturing Agreement

  3/5/2013

• DBV Technologies Reports Full Year 2012 Financial Results and Provides R&D Update

  3/4/2013

• DBV Technologies Reports Full Year 2012 Topline and Provides an Update on R&D Activities

  1/31/2013

• DBV Technologies and INRA Receive Funding to Develop Pediatric Bronchiolitis ("RSV") Vaccine: RSV-NanoViaSkin

  1/15/2013

• DBV Technologies' 2013 Financial Calendar

  12/18/2012

• DBV Technologies and Centre d'Immunologie de Marseille-Luminy (CIML) Enter in a Collaboration Agreement

  10/16/2012

• DBV Technologies Initiates VIPES Phase IIb Clinical Study, the First Global Trial Ever in Desensitization of Peanut-Allergic Children and Adults

  8/2/2012

• DBV Technologies Welcomes Mr. Stef Koppelman as Its New General Scientific Advisor

  7/19/2012

• DBV Technologies: Positive Interim Clinical Data in Peanut Allergic Children Treated With VIASKIN PEANUT

  6/18/2012

• DBV Technologies Presents Detailed Results of a Clinical Study Showing That VIASKIN® Is Safe and Well-Tolerated by Peanut-Allergic Patients at the European Academy of Allergology and Clinical Immunology Congress

  6/18/2012

• Professor Hugh Sampson Joins Scientific Advisory Board of DBV Technologies

  5/31/2012